Mevalonate kinase deficiency syndrome: Single center experience
The aim of this study was to analyze the clinical, laboratory and molecular genetic data of 26 patients (15 boys, 11 girls) diagnosed with mevalonate kinase deficiency syndrome (MKD). Subjects and methods . The age of MKD manifestation ranged from 0 to 30.0 months (M – 1.5 months). Clinical manifest...
Saved in:
Published in: | Nauchno-prakticheskai͡a︡ revmatologii͡a Vol. 59; no. 3; pp. 326 - 334 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
IMA PRESS LLC
15-07-2021
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The aim
of this study was to analyze the clinical, laboratory and molecular genetic data of 26 patients (15 boys, 11 girls) diagnosed with mevalonate kinase deficiency syndrome (MKD).
Subjects and methods
. The age of MKD manifestation ranged from 0 to 30.0 months (M – 1.5 months). Clinical manifestations and their severity were extremely diverse: from symptoms resembling Marshall’s syndrome to severe systemic manifestations with respiratory failure, hepatosplenomegaly and pancytopenia.
Results/Conclusion
. All patients had homozygous/compound-heterozygous mutations in the
MVK
gene, including 10 newly described variants. In all 20 patients, who have been treated with IL-1 inhibitors long enough to assess the effect of the treatment, drastic improvement of the condition was noted, but only in 17/20 patients achieved full remission. |
---|---|
ISSN: | 1995-4484 1995-4492 |
DOI: | 10.47360/1995-4484-2021-326-334 |